According to Jeff LaBerge of San Diego, there exist two primary types of stem cell technologies: autologous, which uses the patients’ own cells and allogeneic, which use cells from a donor. Both transplants begin in the same way, with the harvest of cells from the donor’s body.
Jeff LaBerge of San Diego says at present, stem cell therapy remains a highly fragmented, niche industry, with only a handful of actually “approved” products. Currently, most treatments are bone marrow or blood in transplant procedures to treat patients with cancer and disorders of the blood and immune system. Jeff LaBerge, San Diego also state that its participants are primarily clinical stage private companies and small-mid-cap public bio/pharma companies, with a few big-pharma companies involved in later stage products.
Per Jeff LaBerge of San Diego the global stem cells market size was valued at USD 11.89B* in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 11.4% from 2022 to 2030 . These growth rates may be underestimated given the potential to treat diseases with significant unmet needs. The current market share is split as follows:
*Note: The estimated size of the global stem cell markets varies drastically between different industry publications; from ~$1B – $15B:
Historically, Jeff LaBerge, San Diego states that allogenic therapies have been favored due to their ability to scale and produce “off-the-shelf” treatments, but they carry with them high rejection and other risks. Moving forward, Jeff LaBerge, San Diego says that autologous therapy is expected to expand at a more lucrative CAGR due to their safety, manufacturing improvements and an increased emphasis on “personalized medicines”.
Per Jeff LaBerge of San Diego the stem cell manufacturing market is experiencing vast growth and is expected to reach a value of USD 17,469.6 Million by 2023 at a CAGR of around 17.5% with the North American region dominating the market. Over the past few years, there has been significant growth in awareness pertaining to the therapeutic effectiveness of stem cells, which has in turn has led to the expansion of the global stem cell manufacturing market. Major factors driving market revenue growth include increasing use of stem cells to treat various diseases, rising stem cell-based research activities, and growing funding from private and public organizations for stem cell-based research. Technological advancements in cell therapy and an increased emphasis on the development of personalized medicines are further contributing to market growth.
For numerous of reasons, Jeff LaBerge of San Diego states the sector has experienced a shortage of qualified GMP manufacturing capacity, enabling such manufacturers to charge premium prices for their services. This scenario is expected to continue for years to come.
[1] https://www.grandviewresearch.com/industry-analysis/stem-cells-market
[2] https://www.globenewswire.com/en/news-release/2019/05/08/1819508/0/en/Stem-Cell-Manufacturing-Market-to-Garner-USD-17-469-6-Mn-by-2023-End-Funding-In-Stem-Cell-Based-Research-Boost-The-Stem-Cell-Manufacturing-Industry-Growth.html
Artificial intelligence is becoming an increasingly important layer within modern financial technology, particularly as traders…
From the desk of the Editorial Chief of Staff AI errors are entering the scientific…
Modern life is filled with constant notifications, endless information, and digital conversations that rarely pause.…
Termites are often called "silent destroyers" — and for good reason. These pests are widely…
As the artificial intelligence industry continues to expand, it is becoming increasingly common for companies…
Cities are increasingly competing not simply through iconic landmarks but by offering complete, connected experiences…